Axogen Prices $208.7M Offering at $42.50/Share to Fund BioCircuit Acquisition
AXGN has more than doubled off its 52-week low of $15.27 on elevated volume (3.0× avg).
Summary
Axogen priced a 4.91 million share offering at $42.50 per share, raising approximately $195.5 million to fund its $200 million BioCircuit acquisition. The deal is dilutive to new investors and includes a 90-day insider lock-up.
Key Events · Financing and Capital Events · AXGN
-
Offering Priced at $42.50/Share
4,910,000 shares priced at $42.50 each, a 10% discount to the $47.27 last reported sale price on September 9, 2026. Gross proceeds total $208.7 million.
-
Net Proceeds of $195.5M
After $12.5 million in underwriting discounts and $700,000 in estimated expenses, Axogen nets approximately $195.5 million (or $224.8 million if the 736,500-share option is fully exercised).
-
Immediate Dilution of $34.92/Share
Net tangible book value per share rises from $4.63 to $7.58 after the offering, but new investors pay $42.50 — an immediate dilution of $34.92 per share.
-
Underwriting Syndicate and Lock-Up
BofA, Jefferies, Wells Fargo, Mizuho, and Lake Street underwrite the deal at a 6% discount ($2.55/share). Directors and executives are subject to 90-day lock-up agreements.
Analysis · AXGN · Industrial Applications And Services
Axogen finalized the terms of its $208.7 million public offering, pricing 4.91 million shares at $42.50 each — a 10% discount to the $47.27 last reported sale price on September 9, 2026. The offering is the funding mechanism for the $200 million BioCircuit acquisition announced earlier today. Net proceeds of approximately $195.5 million will cover the purchase price and related fees. The deal is dilutive: new investors pay $42.50 for shares with a net tangible book value of only $7.58 after the offering, representing $34.92 per share of immediate dilution. The underwriting syndicate — BofA, Jefferies, Wells Fargo, Mizuho, and Lake Street — will receive a 6% discount ($2.55 per share). A 90-day lock-up on directors and executives signals confidence but also restricts near-term insider selling. The offering is not conditioned on the acquisition closing, meaning Axogen will retain the capital for general corporate purposes if the deal falls through.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.6% of the 1805 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AXGN was trading at $42.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $15.27 to $52.91. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.